Predicting Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Lenvatinib by Using the Up7-ALBI...

Area of Science:

• Hepatocellular Carcinoma Research
• Oncology Prognostics
• Medical Scoring Systems

Background:

• Lenvatinib is a key treatment for unresectable hepatocellular carcinoma (HCC).
• Existing prognostic models for HCC often fail to integrate both tumor burden and liver function.
• There is a need for improved prognostic tools to guide treatment decisions in HCC.

Purpose of the Study:

• To develop and validate a novel scoring system, the Up7-ALBI score, for predicting survival in patients with unresectable HCC receiving lenvatinib.
• To integrate tumor burden (Up-to-7 criteria) and liver function (albumin-bilirubin grade) into a single prognostic model.
• To assess the prognostic value of the Up7-ALBI score compared to existing models.

Main Methods:

• A multicenter, retrospective study of 205 patients with unresectable HCC treated with lenvatinib.
• Assessment of tumor burden using the Up-to-7 criteria and liver function using the albumin-bilirubin (ALBI) grade.
• Development of the Up7-ALBI score and validation in an independent cohort of HCC patients receiving immunotherapy.

Main Results:

• The Up7-ALBI score effectively stratified patients into low-, intermediate-, and high-risk groups with significantly different overall survival (30.8 vs. 14.2 vs. 9.3 months, p < 0.01).
• Exceeding the Up-to-7 criteria and an ALBI grade of 2 or 3 were independent risk factors for overall survival.
• The Up7-ALBI score demonstrated superior prognostic performance compared to the BCLC stage and ALBI grade alone (AIC values: 1170 vs. 1203 and 1174).

Conclusions:

• The Up7-ALBI score is a novel, effective tool for stratifying survival outcomes in unresectable HCC patients treated with lenvatinib.
• This score integrates crucial prognostic factors: tumor burden and liver function.
• Further validation in larger cohorts and diverse systemic therapies is recommended to confirm its clinical utility.